INMD - Hot Stocks: SAIL takeover deal; INMD hits low; VERU jumps on clinical data; ZNTL falls

Wall Street posted another day of losses on Monday, as technology retreated and volatility jumped. The Nasdaq led the decline, falling more than 2% on the session. Clinical trial data decided the fates of a couple of drug developers during the session. Veru (VERU) nearly tripled amid positive results from its investigative COVID treatment. Meanwhile, data on a cancer drug weighed on shares of Zentalis Pharmaceuticals (ZNTL). In other news, SailPoint (NYSE:SAIL) soared after it agreed to be purchased by a private equity firm. On the other side of the spectrum, InMode (INMD) dropped to a new 52-week low, despite Q1 earnings and revenue projections that beat analysts' expectations. Standout Gainer Shares of Veru (VERU) soared on news that its investigational COVID-19 therapy showed strong results in a recent late-stage trial. The data sent the stock higher by more than 180%. The company said its sabizabulin showed a statistically meaningful

For further details see:

Hot Stocks: SAIL takeover deal; INMD hits low; VERU jumps on clinical data; ZNTL falls